21:20 , Feb 3, 2017 |  BC Week In Review  |  Company News

Abilita deal

Abilita partnered with an undisclosed pharmaceutical company to use its EMP membrane protein evolution platform to discover and develop proteins that target GPCRs. Abilita will receive an upfront payment and is eligible for milestones. Abilita...